(Q43111743)

English

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

scientific article published on 22 January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba (English)

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

0 references

Cryptococcus neoformans

1 reference

based on heuristic

inferred from title

5

object named as

Teun Boekhout

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Jacques F. Meis

6

object named as

Jacques F Meis

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

author name string

Maria-Teresa Illnait-Zaragozi

1

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Gerardo F Martínez

2

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Ilse Curfs-Breuker

3

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Carlos M Fernández

4

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

language of work or name

0 references

publication date

22 January 2008

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

52

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

4

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

1580-1582

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Antifungal agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Posaconazole: a broad-spectrum triazole antifungal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Management of systemic fungal infections: alternatives to itraconazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Correlation of fluconazole MICs with clinical outcome in cryptococcal infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

25 May 2018

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

15 August 2018

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

15 August 2018

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2292518

15 August 2018

[Minimum inhibitory concentration of amphotericin B in yeasts of medical interest]

1 reference

https://pubmed.ncbi.nlm.nih.gov/18212095

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.01384-07

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43111743&oldid=1981183577"